STOP 301: A Phase 3, open‐label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD(®)) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients

OBJECTIVE: To report the safety, tolerability, exploratory efficacy, and patient acceptability of INP104 for the acute treatment of migraine from the Phase 3 STOP 301 trial. BACKGROUND: Dihydroergotamine (DHE) has long been used to treat migraine, but intravenous administration is invasive, frequent...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Timothy R., Winner, Paul, Aurora, Sheena K., Jeleva, Maria, Hocevar‐Trnka, Jasna, Shrewsbury, Stephen B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Submissions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292844/
https://www.ncbi.nlm.nih.gov/pubmed/34363701
http://dx.doi.org/10.1111/head.14184

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292844/
https://www.ncbi.nlm.nih.gov/pubmed/34363701
http://dx.doi.org/10.1111/head.14184

Ejemplares similares